Mersana Therapeutics, Inc.

223 articles about Mersana Therapeutics, Inc.

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023

  5/4/2023

  Mersana Therapeutics, Inc. announced that on May 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 77,550 shares of its common stock and restricted stock unit awards to acquire an aggregate of 65,715 shares of its common stock, to four new employees whose employment commenced in April 2023.

• Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

  5/3/2023

  Mersana Therapeutics, Inc. today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20 p.m. Eastern Time.

• Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

  5/2/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023.

• Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

  4/26/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced the acceptance of multiple abstracts for poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place in Chicago from June 2-6, 2023.

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 06, 2023

  4/6/2023

  Mersana Therapeutics, Inc. announced that on April 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 77,550 shares of its common stock and restricted stock unit awards to acquire an aggregate of 132,925 shares of its common stock, to 10 new employees whose employment commenced in March 2023.

• Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

  3/13/2023

  Mersana Therapeutics, Inc. today announced that the Phase 1 trial of XMT-2056 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA).

• Mersana Therapeutics Provides Statement About SVB

  3/11/2023

  Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, provided an update about its capital resources.

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Mersana Therapeutics, Inc. announced that on March 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of restricted stock unit awards to acquire an aggregate of 44,930 shares of its common stock, to four new employees whose employment commenced in February 2023.

• Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

  2/21/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023.

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Mersana Therapeutics, Inc. announced that on February 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 42,000 shares of its common stock and restricted stock unit awards to acquire an aggregate of 97,665 shares of its common stock, to 10 new employees whose employment commenced in January 2023.

• Mersana Therapeutics to Present at Upcoming Investor Conferences - February 02, 2023

  2/2/2023

  Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences:

• Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

  2/1/2023

  Mersana Therapeutics, Inc. today announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in platinum-sensitive ovarian cancer.

• Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

  1/25/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate.

• Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

  1/6/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones for 2023.

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2023

  1/6/2023

  Mersana Therapeutics, Inc. announced that on January 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 26,700 shares of its common stock, to five new employees whose employment commenced in December 2022.

• Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

  12/22/2022

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets.

• Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

  12/22/2022

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to two targets.

• European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

  12/14/2022

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the European Commission (EC) has designated upifitamab rilsodotin (UpRi) as an orphan medicinal product for the treatment of ovarian cancer.

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  Mersana Therapeutics, Inc. announced that on December 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 16,425 shares of its common stock and restricted stock unit awards to acquire an aggregate of 14,175 shares of its common stock, to two new employees whose employment commenced in November 2022.

• Mersana Therapeutics to Present at 2022 Jefferies London Healthcare Conference

  11/8/2022

  Mersana Therapeutics, Inc. announced that members of management will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 3:50 p.m. GMT.